ArticleJACC. Asia2026
Prognostic Value of Periprocedural Pulmonary Artery Pulsatility Index in Patients After Transcatheter Aortic Valve Replacement.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pulmonary artery pulsatility index (PAPi) is a hemodynamic index that reflects right ventricular function. However, the association between PAPi and prognosis in patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR) remains unclear.
objectivesThis study aimed to determine how periprocedural changes in the PAPi are associated with patients' prognosis after TAVR.
methodsOf the 405 consecutive patients who underwent TAVR for severe aortic stenosis at Hiroshima University Hospital, those with available periprocedural right heart catheter data were included in this study. Patients were divided into 2 groups with a cutoff PAPi value of 3.11 post-TAVR determined by the receiver-operating characteristic curve for the primary endpoint. The primary endpoint was the composite of all-cause mortality and hospitalization caused by heart failure. The secondary endpoint was all-cause mortality. Additionally, factors in the nonimproved PAPi group were investigated.
resultsThis study enrolled 238 patients. The median follow-up was 405.5 days (Q1-Q3: 353-861 days). A lower PAPi was associated with an increased risk of the primary endpoint (23.3% vs 9.9%; log-rank P < 0.001). After multivariate Cox proportional hazard analysis, post-TAVR PAPi >3.11 was still predictive factor for the primary endpoint (HR: 3.04; 95% CI: 1.30-7.13; P = 0.011). Furthermore, the secondary endpoint was significantly increased in lower PAPi group (log-rank P = 0.010). A nonimproved PAPi predictor was pre-TAVR aortic valve mean pressure gradient in multivariate analysis (OR: 1.02; 95% CI: 1.01-1.04; P = 0.003).
conclusionsThe post-TAVR PAPi was associated with all-cause mortality and heart failure hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.